Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure

Hepatology

Volumn 59, Issue 3, 2014, Pages 1084-1093

  Metushi, Imir G ^a   Sanders, Corron ^c,ad   Lee, W M ^ae   Larson, Anne M ^d   Liou, Iris ^d   Davern, Timothy ^e,f   Fix, Oren ^e   Schilsky, Michael ^g,h   McCashland, Timothy ⁱ   Hay, J Eileen ^j   Murray, Natalie ^k   Shaikh, A Obaid S ^l   Blei, Andres ^m   Ganger, Daniel ^m   Zaman, Atif ⁿ   Han, Steven H B ^o   Fontana, Robert ^p   McGuire, Brendan ^q   Chung, Raymond T ^r   Smith, Alastair ^s   Brown, Robert ^t   Crippin, Jeffrey ^u   Harrison, Edwin ^v   Reuben, Adrian ^w   Munoz, Santiago ^x   Reddy, Rajender ^y   Stravitz, R Todd ^z   Rossaro, Lorenzo ^aa   Satyanarayana, Raj ^ab   Hassanein, Tarek ^ac   Samuel, Grace ^ad   Lalani, Ezmina ^ad   Pezzia, Carla ^ad   Attar, Nahid ^ad   Hynan, Linda S ^ad   Durkalski, Valerie ^w   Zhao, Wenle ^w   Dillon, Catherine ^w   Battenhouse, Holly ^w   Goddard, Tomoko ^w   Lee, William M ^c   Uetrecht, Jack ^a,b   more..

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h YALE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^j MAYO CLINIC   (United States)

^k BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^l UNIVERSITY OF PITTSBURGH   (United States)

^m NORTHWESTERN UNIVERSITY   (United States)

ⁿ UNIVERSITY OF OREGON   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p UNIVERSITY OF MICHIGAN   (United States)

^q UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^r MASSACHUSETTS GENERAL HOSPITAL   (United States)

^s DUKE UNIVERSITY MEDICAL CENTER   (United States)

^t Och Spine at New York Presbyterian Hospitals   (United States)

^u WASHINGTON UNIVERSITY   (United States)

^v MAYO CLINIC   (United States)

^w MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^x ALBERT EINSTEIN MEDICAL CENTER   (United States)

^y UNIVERSITY OF PENNSYLVANIA   (United States)

^z VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^aa UNIVERSITY OF CALIFORNIA   (United States)

^ab MAYO CLINIC   (United States)

^ac UNIVERSITY OF CALIFORNIA   (United States)

^ad UNIVERSITY OF TEXAS   (United States)

^ae NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 ANTIBODY; ISONIAZID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; ISONIAZID INDUCED LIVER FAILURE; LIVER FAILURE; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROPHYLAXIS; TOXIC HEPATITIS; WESTERN BLOTTING; YOUNG ADULT;

ADULT; AGED; ANTIBODIES; ANTITUBERCULAR AGENTS; ARYL HYDROCARBON HYDROXYLASES; AUTOANTIBODIES; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 CYP3A; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; ISONIAZID; LIVER FAILURE; MALE; MICROSOMES, LIVER; MIDDLE AGED; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 84896690558     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26564     Document Type: Article

References (26)

1. Center for Disease Control and Prevention. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection-United States, 2004-2008. MMWR 2010;59:224-229.
2. Maddrey WC, Boitnott JK. Isoniazid hepatitis. Ann Intern Med 1973;79:1-12.
3. Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther 2011;89:911-914.
4. Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR, Nelson SD. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 1976;84:181-192.
5. Nelson SD, Mitchell JR, Timbrell JA, Snodgrass WR, Corcoran GB. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science 1976;193:901-903.
6. Timbrell JA, Mitchell JR, Snodgrass WR, Nelson SD. Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo. J Pharmacol Exp Ther 1980;213:364-369.
7. Metushi IG, Nakagawa T, Uetrecht J. Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats. Chem Res Toxicol 2012;25:2567-2576.
8. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1999.
9. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975;69:289-302.
10. Maddrey WC. Isoniazid-induced liver disease. Semin Liver Dis 1981;1:129-133.
11. Ng W, Lobach AR, Zhu X, Chen X, Liu F, Metushi IG, et al. Animal models of idiosyncratic drug reactions. Adv Pharmacol 2012;63:81-135.
12. Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;52:2065-2076.
13. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-954.
14. Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010;51:2117-2126.
15. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003;37:924-930.
16. Polasek TM, Elliot DJ, Somogyi AA, Gillam EM, Lewis BC, Miners JO. An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol 2006;61:570-584.
17. Pohl LR, Kenna JG, Satoh H, Christ D, Martin JL. Neoantigens associated with halothane hepatitis. Drug Metab Rev 1989;20:203-217.
18. Bourdi M, Chen W, Peter RM, Martin JL, Buters JT, Nelson SD, Pohl LR. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 1996;9:1159-1166.
19. Robin MA, Maratrat M, Le Roy M, Le Breton FP, Bonierbale E, Dansette P, et al. Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera. J Clin Invest 1996;98:1471-1480.
20. Nishimura Y, Kurata N, Sakurai E, Yasuhara H. Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. J Pharmacol Sci 2004;96:293-300.
21. Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother 2001;45:382-392.
22. Mitchell JR, Long MW, Thorgeirsson UP, Jollow DJ. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest 1975;68:181-190.
23. Warrington RJ, Tse KS, Gorski BA, Schwenk R, Sehon AH. Evaluation of isoniazid-associated hepatitis by immunological tests. Clin Exp Immunol 1978;32:97-104.
24. Warrington RJ, McPhilips-Feener S, Rutherford WJ. The predictive value of the lymphocyte transformation test in isoniazid-associated hepatitis. Clin Allergy 1982;12:217-222.
25. Maria VA, Victorino RM. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 1997;41:534-540.
26. Salazar-Paramo M, Rubin RL, Garcia-De La Torre I. Systemic lupus erythematosus induced by isoniazid. Ann Rheum Dis 1992;51:1085-1087.